September 02, 2022
Vicore update on the AIR phase 2 trial in idiopathic pulmonary fibrosis
Media
August 31, 2022
Emactuzumab designated as an Orphan Medicinal Product in Europe
August 29, 2022
Fusion Pharmaceuticals Announces First Patient Dosed In Phase 1/2 Study Of FPI-1966 In Patients With Advanced Solid Tumors Expressing FGFR3
August 25, 2022
Interim report April – June 2022
August 19, 2022
Vicore announces multiple scientific abstracts and presentations at upcoming conferences during the autumn
August 18, 2022
European Commission approves Oncopeptides’ Pepaxti for the treatment of patients with relapsed refractory multiple myeloma
August 18, 2022
Targovax ASA: Second quarter and first half year 2022 results
August 17, 2022
Vicore IPF interim data selected as an oral “late-breaker” at the ERS congress
August 11, 2022
Aprea Therapeutics Reports Second Quarter 2022 Financial Results and Provides Update on Business Operations
August 11, 2022
Oncopeptides publishes Q2 report 2022